Aeon Biopharma Inc (AEON)

$0.43 -0.03 (-6.43%)
Market Cap 4.85M
Revenue (ttm) 0.00
Net Income (ttm) 42.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 215,364
Avg Vol 3,879,350
Day's Range N/A - N/A
Shares Out 10.53M
Stochastic %K 51%
Beta 0.35
Analysts Strong Sell
Price Target $359.71

Latest News on AEON

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Apr 25, 2025, 4:05 PM EDT - 15 hours ago

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

Apr 21, 2025, 4:10 PM EDT - 4 days ago

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

Apr 21, 2025, 4:05 PM EDT - 4 days ago

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

AEON Biopharma Announces CEO Transition

Mar 27, 2025, 4:05 PM EDT - 4 weeks ago

AEON Biopharma Announces CEO Transition

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 4:05 PM EDT - 4 weeks ago

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

Mar 4, 2025, 8:00 AM EST - 7 weeks ago

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

AEON Biopharma, Inc. Announces Reverse Stock Split

Feb 24, 2025, 2:00 PM EST - 2 months ago

AEON Biopharma, Inc. Announces Reverse Stock Split

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Feb 7, 2025, 4:05 PM EST - 2 months ago

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

Jan 7, 2025, 9:37 AM EST - 3 months ago

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

Jan 3, 2025, 8:02 PM EST - 4 months ago

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:05 PM EST - 5 months ago

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 19, 2024, 4:05 PM EDT - 8 months ago

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 4:05 PM EDT - 9 months ago

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

May 29, 2024, 8:00 AM EDT - 11 months ago

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

AEON Biopharma Reports First Quarter 2024 Financial Results

May 14, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports First Quarter 2024 Financial Results

AEON Biopharma Provides Update on Development Pipeline

May 9, 2024, 8:00 AM EDT - 1 year ago

AEON Biopharma Provides Update on Development Pipeline

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

May 3, 2024, 7:00 AM EDT - 1 year ago

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

Mar 30, 2024, 10:53 PM EDT - 1 year ago

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 4:15 PM EDT - 1 year ago

AEON Biopharma Announces Redemption of Public Warrants

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 29, 2024, 3:45 PM EDT - 1 year ago

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

Mar 19, 2024, 4:30 PM EDT - 1 year ago

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

Mar 19, 2024, 4:29 PM EDT - 1 year ago

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Jan 18, 2024, 4:05 PM EST - 1 year ago

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

Dec 12, 2023, 8:00 AM EST - 1 year ago

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

AEON Biopharma Reports Third Quarter 2023 Financial Results

Nov 13, 2023, 8:15 AM EST - 1 year ago

AEON Biopharma Reports Third Quarter 2023 Financial Results

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

Oct 19, 2023, 4:05 PM EDT - 1 year ago

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

Aug 29, 2023, 8:00 AM EDT - 1 year ago

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

Aug 24, 2023, 8:00 AM EDT - 1 year ago

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

Aug 16, 2023, 7:00 AM EDT - 1 year ago

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

Jul 24, 2023, 7:00 AM EDT - 1 year ago

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update